Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Retrospective Observational Study of Adult Patients With Early-stage HER2-positive Breast Cancer, Treated With Neratinib as Extended Adjuvant Therapy in the Context of the European Early Access Program (NEAR)

NCT05599334 is registered in ClinicalTrials.gov with Pierre Fabre Medicament as lead sponsor.

NCT NCT05599334
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05599334 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Retrospective Observational Study of Adult Patients With Early-stage HER2-positive Breast Cancer, Treated With Neratinib as Extended Adjuvant Therapy in the Context of the European Early Access Program (NEAR)
Lead sponsor
Pierre Fabre Medicament
Phase
Observational
Overall status
Completed
Start date
July 5, 2022
Completion date
January 30, 2023
Enrollment
111 (actual)
Sites
25

Conditions

As the registry lists them; a condition with its own page is linked.

adjuvant therapy, breast cancer, her2-positive breast cancer